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Summary
Allergen specific CD4+ T cell clones generated from allergic individuals have been shown to
produce increased levels of the cytokine interleukin 4 (IL-4), compared to allergen specific clones
generated from nonallergic individuals. This difference between CD4+ T cells from allergic and
nonallergic individuals with regard to cytokine production in response to allergen is thought
to be responsible for the development of allergic disease with increased IgE synthesis in atopic
individuals. We examined the production ofIL-4 in subjects with allergic rhinitis and in allergic
individuals treated with allergen immunotherapy, a treatment which involves the subcutaneous
administration of increasing doses of allergen and which is highly effective and beneficial for
individuals with severe allergic rhinitis. We demonstrated that the quantity of IL-4 produced
by allergen specific memory CD4+ T cells from allergic individuals could be considerably
reduced by in vivo treatment with allergen (allergen immunotherapy). Immunotherapy reduced
IL-4 production by allergen specific CD4+ T cells to levels observed with T cells from non-
allergic subjects, or to levels induced with nonallergic antigens such as tetanus toxoid. In most
cases the levels of IL-4 produced were inversely related to the length of time on immunotherapy.
These observations indicate that immunotherapy accomplishes its clinical effects by reducing IL-4
synthesis in allergen specific CD4+ T cells. In addition, these observations indicate that the
cytokine profiles of memory CD4+ T cells can indeed be altered by in vivo therapies. Thus,
the cytokine profiles of memory CD4+ T cells are mutable, and are not fixed as had been
suggested by studies of murine CD4+ memory T cells. Finally, treatment of allergic diseases
with allergen immunotherapy may be a model for other diseases which may require therapies
that alter inappropriate cytokine profiles of memory CD4+ T cells.
Although allergen immunotherapy is recognizedas highly
1 .1 effective in the treatment ofpatients with severe allergic
rhinitis (1-4), the specific immunologic mechanism(s) by
which immunotherapy achieves its effects has not been fully
elucidated. Several studies have demonstrated that immuno-
therapy, which involves the subcutaneous administration of
increasing doses of allergen, induces a rise in IgG blocking
antibodies, particularly of IgG4 (3, 5). Other studies have
demonstrated that CD8+ suppressor cells are generated
during immunotherapy which modulate allergen-specific IgE
production (6). However, both of these observations remain
controversial.
Recent advances in our understanding of the immunolog-
ical basis of allergic disease suggest that the production by
CD4+ T cells of increased quantities of cytokines such as
IL-4, which is critical in the induction of IgE synthesis (7-9),
and IL-5, which is an important eosinophil differentiation
factor (10-12), determines whether allergic disease develops
in a given individual (13). Thus, it has been demonstrated
that allergen-specific CD4+ T cells isolated from patients
with allergic diseases such as asthma and allergic rhinitis pro-
duce higher levels of IL-4 and IL-5 compared to allergen-
specific CD4+ T cells obtained from nonallergic individuals
(14-18). The purpose of our study therefore was to inves-
tigate whether allergen immunotherapy in allergic individ-
uals causes a reduction in the amount of IL-4 produced by
allergen specific CD4+ T cells.
Materials and Methods
StudyPopulation.
￿
10 patients on immunotherapy were studied,
and all had histories of severe seasonal allergic rhinitis before the
start of immunotherapy, with positive immediate skin test reac-
tivity to dust mite antigen Dermatophagoides farinae (Der. f)'
1 Abbreviations used in this paper. Der. f ., Dermatophagoides farinae (dust
mite); Lol. p, Loliumperrene(rye grass pollen); Sl,stimulation index; TT,
tetanus toxoid.
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initiation of immunotherapy. These patients were treated with
aqueous extracts of Dermatophagoides farinaelDermatophagoides
pteronyssinus and/or aqueous extracts of grass pollen administered
subcutaneously, and were receiving maintenance (highest) doses
of allergen (500-1,000 Au/dose) once every 4-6 wk. 10 allergic,
untreated, matched control subjects had a similarhistory of severe
seasonal allergic rhinitis, as well as positive skin test reactivity to
the same allergens. All patients gave informed consent, and ex-
perimental protocolswere approved by theStanford University Ad-
ministrative Panel on Human Subjects in Medical Research.
Symptom Scoring.
￿
Allergy symptoms ofthesubjects were scored
in termsof (a) episodes ofsneezing and/or nasalpruritis, (b)rhinor-
rhea and/or nasalblockage, and their frequencyof medication use,
both (c) oral and (d) topical nasal spray medication. A score be-
tween0and 10 wasgiven foreach parameterandthetotalsymptom
score represented the sumof the individual scores. Patients on im-
munotherapy were evaluatedwith both a pre-therapy and current
symptom score whereas untreatedcontrol allergic donors hadonly
current symptoms evaluated.
Table 1 . Patient Characteristics
mean age = 33.9 years
na, not applicable
nd, not done
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Antigens.
￿
Allergenic extract ofLol. p pollen (Berkeley Biolog-
icals, Berkeley, CA), or purified Lol. p, group 1 antigen (NIAID,
Bethesda, MD) wasused at afinalconcentrationof 50 pg/ml. Par-
tially purified housedust mite (Derf) antigen preparation wasgener-
ously provided by S. Dreborg (Pharmacia; Stockholm, Sweden) at
105 BE/ml, and was used at a finalconcentration of 1:100 (vol/vol)
in culture. The tetanus toxoid (TT) antigen preparation (Mass. Dept.
of Public Health) was used in culture at 5 Fig/ml.
Quantitation ofSerum IgE.
￿
Theamount of totalIgEin theserum
of subjects was determined by ELISA, as previously described (9).
Proliferation Assay.
￿
PBMC were isolated from heparinized blood
by flotation over Ficoll-Hypaque (Sigma Chemical Co., St. Louis,
MO), as previously described (9). PBMC (2 x 105/well) from
each donor were cultured in triplicate in 96-well plates in media
aloneor with appropriate concentrations ofantigen. At day 5, cul-
tures were pulsed with ['H]thymidine and harvested 18 h later.
Incorporation of ['H]thymidine (cpm) was then determined by
scintillation counting.
Depletion ofCD8-Pbative Cells.
￿
PBMC were suspendedin RPMI-
1630 at 12.5 x 106 cells/ml and depleted of CD8' cells by addi-
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Donor Yrs on
# therapy Age Sex
Atopic
status
Skin test
Immediate
Lol.p. De,.f
reactivity
Late-phase
Lol.p. Derf.
Allergic untreated controls
1 0 21 M rhinitis + - - na
2 0 41 M rhinitis, dermatitis + + + +
3 0 24 M rhinitis - + na ±
4 0 45 F rhinitis, asthma + + + +
5 0 21 F rhinitis + - + na
6 0 32 M rhinitis + - + na
7 0 23 M rhinitis + - + na
8 0 17 F rhinitis, asthma - + nd nd
9 0 36 F rhinitis + - + na
10 0 42 F rhinitis + - + na
mean age = 30.2 years
Immunotherapy patients
1 0.9 37 F rhinitis + + nd nd
2 2 29 F rhinitis
3 3 41 F rhinitis
4 3 33 F rhinitis, asthma
5 4 44 M rhinitis
6 8 39 M rhinitis, asthma
7 3 18 M rhinitis, asthma
8 17 44 F rhinitis, dermatitis
9 7 18 M rhinitis, asthma + + nd nd
10 3 36 M rhinitis, asthmation of anti-OKTS (anti-CD8) mAb followed by the addition of
rabbit complement (Pel-Freez; Brown Deer, WI) as previously de-
scribed (9). Cells treated in this manner were <3% CD8 positive
and >60% CD4 positive.
Preparation ofAntigenpresenting Cells.
￿
APC were prepared by
incubating fresh PBMC (5-8 x 106 cells/ml) in 60-mm plastic
dishes in complete medium for 2 h at 37°C. In some experiments,
PBMC which were previously frozen and stored in liquid N2,
were thawed and used as a source to isolate APC. Nonadherent
cells were removed by gently washing the dishes three times with
warm RPMI 1630 mediacontaining 5% FCS. The remaining ad-
herent cells were then harvested with cold PBS, washed threetimes,
irradiated at 2,500 rad and used as APC.
Cell Cultures.
￿
CD8-depleted PBMC were cultured in 24-well
plastic dishes at 106/ml (Nunc, Naperville, IL) in 90% air, 10%
COZ humidified environment at 37°C with the appropriate an-
tigen: TT, dust mite antigen, or rye grass pollen antigen, as previ-
ously described (17). At day 7 of culture, cells were washed once
in PBS and reculturedwith freshAPC, freshantigen, and 10 U/ml
hrIL2 (Amgen, Thousand Oaks, CA). Between days 7 and 14,
cultures were expanded asnecessary. Previous studies (17, and Secrist,
H., unpublished observations) have demonstrated that antigen/
allergen specific CD4' cells are preferentially expanded in such
cultures. At day 14 of culture, cells were washed three times in
PBS and resuspended in complete medium at 2 x 106/ml with
PHA-P (Difco Laboratories Inc., Detroit, MI; 1:200 [vol/voll) and
1 ng/ml of PMA. After 18 h, supernatants were collected and kept
at -80°C until assayed for cytokine content.
Quantitation ofCytokines.
￿
hlIr2 was measuredbybiologicalassay,
using the murine indicator HT-2 cell line (generously provided by
Dr. Sam Strober, Stanford), as previously described (9). hIL4 and
hIFN-,y were quantified by ELISA, as previously described (17).
Results
Clinical Efficacy ofImmunotherapy Basedon Skin Test Reac-
tivity and Symptom Scoring. The characteristics of patients
on allergen immunotherapy and untreated allergic control
subjects are presented in Table 1. The mean age of im-
munotherapy patients and the untreated controls was 34 and
30, respectively. The duration ofimmunotherapy for patients
ranged from 1 to 17 yr (mean, 5 yr). All donors exhibited
positive immediate skin-test reactivity to appropriate allergens.
None ofthe immunotherapy patients exhibited late-phase skin
test reactivity (19),which is known to diminish with immuno-
therapy (20), whereas seven of the nine untreated allergic sub-
jects tested exhibited positive late-phase skin test reactions
(Table 1). Subjects in both treated and untreated groups had
similar pre-therapy symptom scores, and those on immuno-
therapy treatment exhibited a marked decrease in allergy symp-
toms (Fig. 1) . Donors were matched for serum IgE levels
(Fig. 2), using data obtained currently for all subjects (post-
therapy levels for immunotherapy patients), with untreated
allergic controls having a mean IgE level of 271 IU/ml, and
the treated immunotherapy patients having a mean level of
340 IU/ml. Subjects with serum IgE levels <50 IU/ml were
excluded from study to ensure that selected individuals had
severe allergic disease.
ProlferativeResponses ofPBMC to Allergen and Nonallergen.
The results ofproliferation studies of freshly isolated PBMC
from immunotherapy patients and untreated allergic controls
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Figure 1.
￿
Symptom scores of untreated allergic control subjects and
of immunotherapy treated patients. Derivation of scores is as described
in the Materials and Methods. The mean score ± SE in the untreated
control group was 22.1 ± 2.33, whilethe mean score ofthe immunotherapy
group was 22.9 ± 1.9 (before therapy) and 9.1 ± 1.6 (post therapy).
in response to Der. f, and Lol. p antigens are presented in
Fig. 3 A. Although the mean stimulation index to allergen
of immunotherapy patients was somewhat lower than that
ofthe untreated controls, as has been previously demonstrated
(21), allergen-specific T cells were present in both groups of
donors. PBMC from subjects who were not allergic to one
of the two allergens, as assessed by immediate skin test reac-
tivity, did not proliferate to that allergen (stimulation index
<1) (Fig. 3 A) .
Proliferative responses ofPBMC from subjects to TT were
also assessed (Fig. 3 B). The mean stimulation indices (31
9.7 for untreated control allergic subjects vs. 24.3 ± 4.6
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Figure 2.
￿
Serum IgE levels of untreated allergic control subjects and
of immunotherapy treated patients. Mean IgE levels of the two groups
were 271 t 85 and 340 ± 140 (P >0.1, Mann-Whitney test), respectively.
10000
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wFigure 3 .
￿
Proliferative responses ofPBMC to allergen (A) and to the
nonallergen TT (B) . Values are presented as the stimulation index (SI),
calculated by dividing the cpm ofantigen-stimulated cultures by the cpm
ofunstimulated cultures. Mean SI ± SE for the untreated group was 12 .1
± 3 .7 and for the immunotherapy group 5.5 ± 1 .0 in response to allergen
(P <0.04, Mann-Whitney test) while the mean SI for the untreated group
in response to TT was 31 ± 9.7 and for the immunotherapy group was
24 .3 ± 4.6 (P >0.3, Mann-Whitney test) . (") Actual values for untreated
control donors #9 and #10 in response to allergen are 47 and 22 .6, respec-
tively. Actual value foruntreated control donor#3 inresponse toTT is 112.2.
for immunotherapy patients) were not significantly different
between the two groups of subjects, although the prolifera-
tive responses to TT were generally greater than that to al-
lergens .
Patients on Immunotherapy Exhibit DecreasedProduction o,fIL-4
in Response to Allergen. To directly examine cytokineproduc-
tion by CD4+ T cells in untreated control subjects and im-
munotherapy patients, PBMC were depleted of CD8+ T
cells and cultured with allergen (Der .f .,
￿
IA P.) or TT Since
we have previously shown that the peak production of IL-4
in vitro requires two stimulations with antigen/allergen (17),
the CD8-depletedPBMC were stimulated twicewith allergen,
after which the cytokine profile of the cells was determined .
As depicted in Fig. 4 A, CD8-depleted PBMC from untreated
allergic controls produced significantly more IL-4 in response
to allergen (7,919 ± 2,480 pg/ml) than that of patients on
immunotherapy (477 ± 169) (P<0.002) . Interestingly, with
one exception, immunotherapy patients exhibiting IL-4 levels
>300 pg/ml (range : 528-2,090 pg/ml) were on immuno-
therapy for the least amount of time (1-3 yr) whereas pa-
tients demonstrating IL-4 levels below 300 pg/ml were on
32000
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Figure 4 .
￿
IL4 production in response to allergen (A) and to the non-
allergenTT (B) . CD8-depleted cells were stimulated with allergen or an-
tigen on day 0, and restimulated on day 7 with the same allergen/antigen .
On day 14, the cultures were harvested, and the cytokine profiles ofcells
determined. Mean ID4 production was 7,919 ± 2,480 pg/ml in the un-
treated control group and 477 ± 169 pg/ml in the immunotherapygroup
(P <0.002, Mann-Whitney test) .immunotherapy for more than three years . In other words,
IL-4 levels were inversely related to the length of time on
immunotherapy.
The PBMC from the untreated control donors produced
significant quantities of IL-4 in response only to allergens
to which they were allergic . Thus, little or no IL-4 was pro-
duced in response to allergens when allergen-specific IgE was
absent in the sera ofthe donor (negative immediate skin test),
or in response to a control nonallergenic antigen, TT (Fig .
4 B, and reference [17]) . The low but detectable levels ofIL-4
from CD8-depletedPBMC in response toTT were comparable
in both donor groups (Fig. 4 B), and were not statistically
different from the IL-4 levels produced by CD8-depleted
PBMC from immunotherapy patients in response to allergens.
This indicated that immunotherapy could reduce allergen-
specific IL-4 synthesis to levels observed with nonallergenic
antigens .
E
J
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Figure 5 .
￿
IL2 production (A) and IFN-y production (B) in response
to allergen. Cultures were performed as described for Fig. 4 . Mean 11.2
production was 81 ± 23 U/ml in the untreated control group and 88
± 30 U/ml in the immunotherapy group (P >0 .3, Mann-Whitney test) .
Mean IFN-y production was 5,069 ± 1,577 pg/ml in the untreated con-
trol group and 12,320 ± 7,050 pg/ml in the immunotherapy group (P
>0.1, Mann-Whitney test) .
IFN-y and IL-2 Production Is Not Significantly Altered in
Immunotherapy Patients. Since in some murine models the
level of IL-4 production was inversely related to the level of
IFN-y production (22, 23), we next asked whether the de-
crease in allergen-specific IL-4 production demonstrated in
immunotherapy patients was accompanied by a corresponding
increase in allergen-specific IL-2 and IFN-y production . As
demonstrated in Fig. 5, production of IL-2 and IFN-y by
CD8-depleted cells from both untreated control and im-
munotherapy patients was variable, but no statistical differ-
ences (P»0.1) were demonstrated in IL-2 orIFN-y produc-
tionbetween the two groups. The amount of IFN-y produced
by allergen stimulated cultures was similar to that observed
in response to TT Thus, while immunotherapy treatment
specifically downregulates IL-4 production in response to al-
lergenic stimulation, there was no discernable effect on the
production of IL-2 and IFN-y .
Discussion
We demonstrated that treatment of individuals suffering
from allergic rhinitis with allergen immunotherapy was as-
sociated with a significant reduction in allergen induced IL-4
synthesis in vitro. The reduced IL-4 synthesis in vitro from
PBMC ofimmunotherapy patients was allergen-specific and
a consistent finding associated with improved clinical symp-
toms. The subjects in our patient and untreated control groups
were closely matched for symptom severity before immuno-
therapy as well as for total IgE in serum . Patients on im-
munotherapy with low total IgE in serum were not included
in our study, even though such levels have been reported to
decrease over time with immunotherapy (24, 25) . We con-
clude therefore from our retrospective study, that immuno-
therapy accomplishes its clinical effects by reducing IL-4
synthesis in allergen specific CD4+ T cells to levels that
approximate those from nonallergic subjects, or to levels ob-
served in response to nonallergens such as TT Consistent
with this idea is our observation that IL-4 production by T
cells from individuals on immunotherapy varies inversely with
the length of time on immunotherapy (Fig. 4, and Secrist,
H ., and C.J . Chelen, manuscript in preparation) . However,
a prospective placebo controlled study examining cytokine
production in CD4+ T cells before, during, and after im-
munotherapy is necessary to confirm our results .
The profile of cytokines produced by antigen-specific
CD4+ T cells has been proposed to determine the type or
form of the immune response that occurs in vivo. For ex-
ample, protective immunity against intracellular pathogens
(e.g., Mycobacteria) requires the development ofTh cells with
cytokine profiles (i.e., IL-2 and IFN-y synthesis [Th1 profile]
[26-29]) that are different from the profiles required for pro-
tective immunity against extracellular bacteria (e.g., Strep-
tococcus pneumonia, requiring IL-4 and IL-5 synthesis [Th2
profile] [9, 26, 30-32]) . It has been proposed that the devel-
opment of inappropriate cytokine profiles gives rise to ab-
normal (nonprotective) immunity resulting in the dissemi-
nation ofinfection, or in the development of allergic disease.
The idea that disease may be caused by the development
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immunity, suggests that therapies for such diseases might
involve modification of the cytokine profile of primed or
memory T cells. In a number of model systems in mice, treat-
ment of the mice before immunization or infection with "im-
mune response modifying agents", such as cytokines or anti-
cytokine monoclonal antibodies, have been shown to indeed
alter the profile of cytokines that develop in such unprimed
T cells (22, 29, 33). Although such agents (e.g., anti-IL-4
mAb or anti-IL-4 receptor mAb) have been proposed for the
treatment of allergic diseases (8, 34), it appears that the cyto-
kine profiles of memory CD4+ T cells (as well as sIgE+ B
cells) are resistent to modification with such agents (35, 36) .
Nonetheless, our study of allergen-specific CD4+ T cells
from allergic individuals demonstrates that allergen specific
IL-4 synthesis can be inhibited with immunotherapy, and that
immunotherapy, in contrast to treatment with anti-IL-4 mAb,
can indeed alter the cytokine profiles of memory T cells.
Although all of our patients on immunotherapy continued
to have positive immediate (IgE mediated) skin tests to al-
lergens, it is likely that the production of allergen-specific
IgE diminished as the amount of allergen-specific IL-4 syn-
thesis decreased with immunotherapy. We believe this to be
the case because none of the immunotherapy patients had
persistence ofallergen-specific late phase cutaneous responses
(19, 20), and because the production of smaller quantities
of IL-4 was associated with lower levels of allergen specific
IgE in the serum of the T cell donor (data not shown).
Further studies are in progress to determine the precise
mechanisms by which immunotherapy modifies cytokine syn-
thesis in CD4+ T cells. Since natural exposure to allergen
occurs generally by inhalation whereas treatment with im-
munotherapy involves subcutaneous administration ofallergen,
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rather than the physical-chemical structure of the allergen
that significantly affects the cytokine profiles that develop in
antigen/allergen specific T cells (37). In addition, since the
amount of allergen administered during immunotherapy is
much greater than the amount inhaled, the antigen dose may
also affect the cytokine profile, possibly by altering the type
of APC or monokines involved (38-41). As shown by our
proliferation studies, allergen specific CD4+ T cells remained
in the peripheral blood of immunotherapy patients, and there-
fore such cells appeared not to be deleted or tolerized during
immunotherapy. Although our study suggests that immuno-
therapy actively modifies the cytokines produced by allergen-
specific CD4+ T cells, it is not clear whether immuno-
therapy alters the profile of a currently existing CD4+ (or
CD8+) T cell population or expands an entirely new popu-
lation of CD4 + T cells.
Although there have been considerable recent improvements
in the symptomatic treatment of patients with allergic rhi-
nitis with the availability of nonsedating 111 histamine an-
tagonists and nasal corticosteroids, treatment with immuno-
therapy, which appears to alterthe underlying immunological
basis of the disease in an allergen-specific way, may be in the
long run a more beneficial modality. Studies such as ours,
which are directed at understanding the underlying mecha-
nisms of immunotherapy, are likely to lead to modifications
in the technique, resulting in methods that are even safer and
more effective in achieving clinical and immunological effects.
Furthermore, immunotherapy with modified forms of an-
tigen may be applicableto other diseases in which inappropriate
cytokine profiles in memory CD4+ T cells require al-
teration.
We gratefully thank Dr. Moon Nahm (Washington University, St. Louis, MO) for anti-IL-4 monoclonal
antibodies; Dr. S. Dreborg (Pharmacia) for the Der.f antigen; Drs. M. Delano, W. McKee, and J. Blessing-
Moore for patient referrals; and Dr. R.H. DeKruyfT for critically reading the manuscript.
Address correspondence to Dr. Dale T. Umetsu, Department of Pediatrics, Rm. H307, Stanford Univer-
sity, Stanford, CA 94305-5119.
Received for publication 4 August 1993.
2128
￿
Allergen Immunotherapy Decreases Interleukin 4 Production
1 . Varney, V.A., M. Gaga, A.J. Frew, V.R. Aber, A.B. Kay, and controlled, specific immunotherapy with standardized extracts.
S.R. Durham. 1991. Usefulness of immunotherapy in patients J. Allergy Clin. Immunol. 99:43.
with severe summer hay fever uncontrolled by antiallergic drugs. 4. Van Metre, TE., D.G. Marsh, and N .F. Adkinson, Jr. 1988.
BMJ (Br. Med. J.). 302:265. Immunotherapy for cat asthma. J. Allergy. Clin. Immunol.
2 . Norman, P.S. 1988. Immunotherapy for nasal allergy. J. Al- 82:1055.
lergy Clin. Immunol. 81:992. 5. Reid,M.J., R.B. Moss, Y.-P. Hsu,J.M. Kwasnicki, TM. Com-
3 . Bousquet, J., W.M. Becker, A. Heijaoui, C.P., I. Chanal, B. merford, and B.L. Nelson. 1986. Seasonal asthma in northern
Lebel, H. Dhivert, and F.B. Michel. 1991. Clinical and im- California: allergic causes and efficacy of immunotherapy. J.
munological reactivityof patients allergic to grass pollens and Allergy Clin. Immunol. 78 :590.
to multiple pollen species. II. Efficacy ofa double-blind, placebo- 6. Rocklin, R.E., A. Sheffer, D.K. Greineder, and K.L. Melmon.1980. Generation of antigen-specific suppressor cells during
allergy desensitization. N . Engl. J Med. 302:1213.
7. Tepper, R.I., D.A. Levinson, B.Z. Stanger, J. CamposTorres,
A.K. Abbas, andPLeder. 1990.11,4 induces allergic-like inflam-
matory diseaseandalters Tcell development in transgenic mice.
Cell. 62:457.
8. Finkelman, F.D., J.F. Urban Jr., M.P. Beckmann, K.A.
Schooley, J.M. Holmes, and I.M. Katons. 1991. Regulation
of murine in vivo IgGandIgEresponsesby a monoclonal anti-
IL-4 receptor antibody. Intl. Immunol. 3:599.
9. DeKruyff, R.H., T Turner, J.S. Abrams, M.A. Palladino, Jr.,
and DT Umetsu. 1989. Induction of human IgE synthesis
by CD4' T cell clones: requirement for interleukin 4 and low
molecularweight B cell growth factor.J. Exp. Med. 170:1477.
10. Walker,C., J.-C. VirchowJr., P.L.B. Bruijnzeel, and K. Blaser.
1991. T cell subsets and their soluble products regulate eo-
sinophilia in allergic and nonallergic asthma.J Immunol. 146:
1829.
11 . Stern, M., L. Meagher, J. Savill, andC. Haslett. 1992. Apop-
tosis in human eosinophils: programmed cell death in the eo-
sinophil leads to phagocytosis by macrophages and is modu-
lated by IL5.J Immunol 148:3543.
12. Coffman, R.L., B.W. Seymour, S. Hudak, J. Jackson, and D.
Rennick. 1989. Antibody to interleukin-5 inhibits helminth-
induced eosinophilia in mice. Science (Wash. DC). 245:308.
13. Umetsu, DT, R.C. Bocian, and R.H. DeKruyff. 1992. Re-
stricted lymphokine synthesis in CD4' helper T cells: new
insights into theregulation ofIgE synthesis andinto thepatho-
genesis ofallergic disease. Pediatric. Asthma Allergy £o Immunol.
6:1.
14. Gaga, M., A.J. Frew,V.A. Varney, andA.B. Kay. 1991. Eosin-
ophil activation and T lymphocyte infiltration in allergen-
induced late phase skin reactions and classical delayed-type
hypersensitivity. J Immunol. 147:816.
15. Robinson, D.S., Q. Hamid, S. Ying, A. Tsicopoulos, J.Barkans,
A.M. Bentley, C. Corrigan, S.R. Durham, andA.B.Kay. 1992.
PredominantTh2-like bronchoalveolar T-lymphocyte popula-
tion in atopic asthma. N. Engl.J Med. 326:298 .
16. Kapsenberg, M.L., E.A. Wierenga,J.D. Bos, and H.M. Jansen.
1991. Functional subsets of allergen-reactive human CD4' T
cells. Immunol. Today. 12:392.
17. Marshall, J., Y Wen, J.S. Abrams, and DT Umetsu. 1993.
In vitro synthesis of IL-4 by human CD4* T cells requires
repeated antigenic stimulation. Cell. Immunol In press.
18 . Durham, S.R., S. Ying, VA. Varney, M.R. Jacobsen, R.M.
Sudderick, I.S. Mackay, A.B. Kay, and Q.A. Hamid. 1992.
CytokinemessengerRNAexpression for IL3, 114, l1r5, and
granulocyte/macrophage-colony-stimulating factor in the nasal
mucosa after local allergen provocation: relationship to tissue
eosinophilia. J. Immunol 148:2390.
19. Kay, A.B., S. Ying, V. Varney, M. Gaga, S.R. Durham, R.
Moqbel, A.J. Wardlaw, andQ. Hamid. 1991.MessengerRNA
expression of the cytokine gene cluster, interleukin 3 (IL-3),
11,4, IL-5, and granulocyte/macrophage colony-stimulating
factor, in allergen-induced late-phase cutaneous reactions in
atopic subjects. J Exp. Med. 173:775.
20. Pienkowski, M.M., P.S. Norman, andL.M. Lichtenstein. 1985.
Suppressionoflate-phase skin reactions by immunotherapy with
ragweed extract. J Allergy Clin. Immunol. 76:729.
21. Evans, R., H. Pence, H. Kaplan, and R.E. Rocklin. 1976. The
effect of immunotherapy on humoral and cellular responses
in ragweed hayfever.J. Clin. Invest. 57:1378.
22. Swain, S.L., A.D. Weinberg,M. English, and G. Huston. 1990.
2129
￿
Secrist et al.
11,4 directs the development of Th2-like helper effectors. J.
Immunol. 145:3796.
23. Fiorentino, D.F., M.W. Bond, andT.R. Mosmann. 1989. Two
types of mouse T helper cell. IV Th2 clones secrete a factor
that inhibits cytokine production by Thl clones.J Exp . Med.
170:2081.
24. Creticos, P.S., T.E. Van Metre, M.R. Mardiney, G.L. Rosen-
berg, P.S. Norman, andN.F. Adkinson Jr. 1984. Doseresponse
of IgE and IgG antibodies during ragweed immunotherapy.
J. Allergy Clin. Immunol. 73:94.
25. Van Metre, TE., Jr., M.F. Adkinson, F.J. Amodio, A. Kagey-
Sobotka, L.M. Lichtenstein, M.R.J. Mardiney, P.S. Norman,
and G.L. Rosenberg. 1982. A comparison ofimmunotherapy
schedules for injection treatment ofragweed pollen hay fever.
J. Allergy Clin. Immunol. 69:181.
26. Del Prete, G.F., M. De Carli, C. Mastromauro, R. Biagiotti,
D. Macchia, P. Falagiani, M. Ricci, andS. Romagnani. 1991.
Purified protein derivative of Mycobacterium tuberculosis and
excretory-secretoryantigen(s) of Toxocara canis expand in vitro
human T cells with stable and opposite (type 1 T helper or
type 2 Thelper) profileofcytokine production.J Clin. Invest.
88:346.
27. Salgame, P., J.S. Abrams, C. Clayberger, H. Goldstein, J.
Convit, R.L. Modlin, and B.R. Bloom. 1991. Differing lym-
phokineprofiles of functional subsets ofhumanCD4andCDS
T cell clones. Science (Wash. DC). 254:279.
28. Pearce, E.J., P. Caspar, J.-M. Gryzch, F.A. Lewis, and A. Sher.
1991. Downregulation ofThl cytokine production accompa-
nies induction of Th2responses by aparasitic helminth, Schisto-
soma mansoni.J. Exp. Med. 173:159.
29. Heinzel, F.P., M.D. Sadick, S.S. Mutha, and R.M. Locksley.
1991. Production of interferon -y, interleukin 2, interleukin
4, and interleukin 10 by CD4+ lymphocytes in vivo during
healing andprogressive murine leishmaniasis. P.N.A.S. 88:7011.
30. Mosmann, TR., and R.L. Coffman. 1987. Twotypes of mouse
helper T-cell clone: implications for immune regulation. Im-
munol. Today. 8:223.
31 . Stevens, TL., A. Bossie, V.M. Sanders, R. Fernandez-Botran,
R.L. Coffman, TR. Mosmann, and E.S. Vitetta. 1988. Regu-
lationofantibody isotype secretionby subsets ofantigen-specific
helper T cells. Nature (Lond.). 334:255.
32. DeKruyfl; R.H., S.-T. Ju, A.J. Hunt, TR. Mosmann, and
DT Umetsu. 1989. Induction ofantigen-specific antibody re-
sponses in primed andunprimed B cells: functional heteroge-
neityamongThl andTh2Tcell clones. J. Immunol 142:2575.
33. Hsieh, C.-S., S.E. Macatonia, C.S.Tripp, S.F.Wolf,A. O'Garra,
and K.M. Murphy. 1993. Development of Thl CD4` T cells
through 11,12 produced by Listeria-induced macrophages.
Science (Wash. DC). 260:547.
34 . Urban, J.F., Jr., I.M. Katona, WE. Paul, andF.D. Finkelman.
1991. Interleukin 4 is important in protective immunity to a
gastrointestinal nematode infection in mice. Proc. Nat. Acad.
Sci. USA. 88:5513.
35. Katona, I.M., J.F. UrbanJr., S.S. Kang, WE. Paul, and F.D.
Finkelman. 1991. IL4 requirements for thegeneration of sec-
ondary in vivo IgE responses.J. Immunol. 146:4215.
36. Gross, A., S.Z. Bens-Sasson, and WE. Paul. 1993. Anti-11,4
diminishes in vivo priming for antigen-specific IL4 produc-
tion by T cells. J. Immunol. 150:2112.
37. Saloga, J., H. Renz, G. Lack, K.L. Bradley, J.L. Greenstein,
G. Larsen, and E.W. Gelfand. 1993.Developmentandtransfer
of immediate cutaneous hypersensitivity in mice exposed to
aerosolized antigen. J. Clin. Invest. 91:133.38. DeKruyff, R.H., Y Fang, and D.T. Umetsu. 1992. IL-4 syn-
thesis by in vivo primed keyhole limpet hemocyanin-specific
CD4* T cells. J. Immunol. 149:3468.
39 . Parish, C.R., andF.Y. Liew. 1972. Immune response to chem-
ically modified flagellin. III. Enhanced cell-mediated immu-
nity during high andlowzone antibody toleranceto flagellin.
J. Exp. Med. 135:298.
40. HayGlass, KT,andB.P. Stefura. 1991. Anti-interferon ytreat-
2130 Allergen Immunotherapy Decreases Interleukin 4 Production
ment blocks the ability of glutaraldehyde-polymerized allergens
to inhibit specific IgE responses. J. Exp. Med. 173:279.
41 . Manetti, R., P. Parronchi, M.G. Giudizi, M.-P. Piccinni, E.
Maggi, G. Trinchieri, and S. Romagnani. 1993. Natural killer
cell stimulatory factor (Interleukin 12 [IL12]) induces Thelper
type I (Thl)-specific immune responses andinhibits the devel-
opment of IA-producing Th cells. J. Exp. Med. 177:1199.